



Next generation therapies to end TB

BUILDING BLOCKS OF ERADICATION



Short, effective,

**UNIVERSAL
REGIMEN**

for all forms of Active TB




Short, effective,

**UNIVERSAL
THERAPY**

for Latent TB

TB Alliance | Drug development pipeline*



*As of November 2024. This document is updated on a quarterly basis.



TB Alliance | Portfolio partners

Toward the first universal regimen



PRETOMANID (Pa)

876PaL

TBAJ-876

LINEZOLID (L)

POTENTIAL FOR FIRST UNIVERSAL REGIMEN



Potential for new compound to replace bedaquiline

If safety profile is appropriate development as a universal regimen will continue

ENROLLMENT COMMENCED 24 OCTOBER 2023 AND COMPLETED 30 AUGUST 2024



 309 participants enrolled at


 21 sites, in

 5 countries and on

 3 continents

Accelerating development and treatment pathways

EFFICIENT CLINICAL TRIAL DESIGN



NCOOS
A Pan-Phase 2 Study


DEVELOPING INNOVATIVE APPROACHES TO SHORTEN TREATMENT, LIKE LAI



Universal
Regimen




Long-Acting
Injectable



Host-Directed
Therapy

Maximizing the impact of our pipeline



CO-DEVELOPMENT FOR ADDITIONAL DISEASES WHEN:


- ✓ Unmet need and compelling science
- ✓ Synergistic with TB work
- ✓ Sources of incremental external funding



✓ **NEWER, MORE POTENT DRUGS**
with properties conducive to LAI formulation – enabling immense treatment shortening

✓ **TRACK RECORD OF LAI SUCCESS**
in other disease areas

✓ **ESTABLISHED CLINICAL TRIAL NETWORKS**
experienced in conducting LTBI trials



Active TB

Approximately
10 MILLION CASES



Latent TB

ONE THIRD
of the world's population


New approaches currently in development to realize the next quantum leap in treatment shortening



The Future of TB Treatment



ONE DAY
to treat latent
TB infections



ONE MONTH
to treat active
TB infections

